9th Course of the European School of Urology Nursing:
Intravesical therapy for NMIBC
12-13 June 2026 in Gdansk, Poland
To enhance nurses’ knowledge, confidence, and practical competence in the delivery of intravesical therapy for patients with non-muscle-invasive bladder cancer (NMIBC). The course aims to standardise practice across Europe, strengthen patient safety, and empower participants to become local trainers and advocates for evidence-based NMIBC care within their institutions.
Aims and objectives
At the end of the course, participants will be able to:
1. Explain the principles and rationale of intravesical therapy in the management of non-muscle-invasive bladder cancer (NMIBC).
2. Differentiate between types of intravesical agents (e.g. BCG, chemotherapy, hyaluronic acid) and their mechanisms of action.
3. Demonstrate safe preparation, administration, and handling procedures for intravesical treatments in clinical practice.
4. Identify contraindications, side effects, and appropriate nursing interventions for managing adverse events.
5. Apply evidence-based guidelines and standard operating procedures to ensure consistency and patient safety.
6. Evaluate strategies for patient assessment through effective communication and education to enhance patient adherence to treatment.
7. Develop the confidence and competence to train colleagues locally, supporting a sustainable “Train-the-Trainer” model for NMIBC care.
Process
To be selected for the course, applicants must be experienced or specialised nurses involved in the care of bladder cancer patients in clinical, outpatient, or community settings. Participants should be motivated to act as local ambassadors for NMIBC best practice and be able to disseminate the knowledge and skills gained during the course to colleagues in their own organisations or regions.
Selection will be based on the information you disclose in this application form, with consideration given to clinical experience, motivation, and potential impact on local practice.
Tasks
Prior to the course, participants must read:
- Four selected scientific articles provided by the organising committee, and
- EAUN Guidelines on Intravesical instillation with mitomycin C and bacillus Calmette-Guérin in non-muscle-invasive bladder cancer (2026)
Before the start of the course, participants are requested to submit a short description of a challenging clinical situation from their own practice involving a bladder cancer patient. These examples will be used to inform workshops and group discussions.
After the course, all participants must complete a post-course evaluation, including:
- Identification of three key messages learned during the course, and
- A brief description of how they plan to disseminate their “train the trainer” knowledge within their local or regional teams.
Registration
The registration fee for the course is €140 (incl. VAT) for EAUN and €185 (incl. VAT) for non-EAUN members. The EAUN books your hotel incl. breakfast for one night, a networking dinner on Friday and reimburses your flight up to €500. Kindly note t
